One in Five State Medicaid Programs Cover Antiobesity Medications
By Lori Solomon HealthDay Reporter
THURSDAY, March 21, 2024 -- As of early 2023, one in five state Medicaid programs covered antiobesity medications, according to a research letter published online March 14 in the Journal of the American Medical Association.
Benjamin Y. Liu, M.D., from Beth Israel Deaconess Medical Center, and Benjamin N. Rome, M.D., from Brigham and Women’s Hospital, both in Boston, examined state Medicaid coverage policies for antiobesity medications and trends in Medicaid reimbursement. The analysis included data from the public Medicaid State Drug Utilization Data (2011 to 2022).
The researchers found that in the first quarter of 2023, 10 of 47 states (21 percent) with public preferred drug lists covered at least one antiobesity medication. Five states (11 percent) had unrestricted coverage of at least one antiobesity medication, while 39 states (83 percent) had unrestricted coverage of at least one of the two diabetes versions of glucagon-like peptide 1 receptor agonists (GLP-1 RAs). During the study period, the number of antiobesity medication prescriptions reimbursed by state Medicaid programs increased more than 1,300 percent due to greater reimbursement of GLP-1 RAs. In 2022, 87 percent of reimbursements for antiobesity medications were for liraglutide (Saxenda) or semaglutide (Wegovy). During the study period, the number of states with documented reimbursements for antiobesity medications increased from 13 to 22.
"In 2021, 40 percent of Medicaid enrollees had obesity," the authors write. "This prevalence, combined with high prices for GLP-1 RAs, raises budgetary concerns; ensuring access to these drugs for the vulnerable Medicaid population requires states or the federal government to negotiate lower prices."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
BMI Cutoff of 30 for Obesity May Be Too High for Middle-Aged, Older Adults
FRIDAY, May 31, 2024 -- The optimal body mass index (BMI) cutoff point appears to be 27 kg/m2 for detecting obesity in middle-aged and older adults, according to a study presented...
Weight Navigation Program Boosts Use of Weight Management Treatments
FRIDAY, May 31, 2024 -- A primary care-based weight navigation program (WNP) is feasible and associated with greater use of weight management treatments (WMT) and weight loss...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.